DSPM
Danish Society for Personalised Medicine

COPENHAGEN

ESPT
European Society of Pharmacogenomics and Personalised Therapy
A Scientific Society for Individualised Medicine

7th ESPT CONGRESS

25-28 October 2023

Copenhagen

Venue
DGI Byen - CPH
Conference Tietgensgade
65 1704 Copenhagen

Under the auspices of

ifcc International Federation of Clinical Chemistry and Laboratory Medicine

EFLM EUROPEAN FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE

www.esptcongress.org

European Society of Pharmacogenomics and Personalised Therapy
www.esptsociety.eu

Welcome letter

The 7th International Congress of the European Society for Pharmacogenomics and Personalised Therapy (#ESPT2023) will be held from Wednesday October 25th to Saturday October 28th in Copenhagen, Denmark.

The #ESPT2023 congress will again bring together leading international scientists and healthcare professionals who are actively working in the fields of Pharmacogenomics and Personalised Therapy.

After successful events in the previous years (Belgrade 2022, Seville 2019, Catania 2017, Budapest 2015, Lisbon 2013, Bled 2011), we are very happy to have our 2023 meeting in Denmark, in collaboration with The Danish Society for Personalised Medicine (#DSPM).

The congress will consist of 30 world class plenary speakers, addressing current aspects and future directions on pharmacogenomics and personalised medicine, including clinical implementation, decision support tools and liquid biopsy analyses.

Keynote Opinion Leaders include Kim Brøsen, Sir Munir Pirmohamed, Matt Brown (Genomics England), Daniel Müller, Espen Molden, Vicky Pratt, Klaus Pantel, Claus Lindbjerg Andersen, Catherina Aix-Panabieres, Ingolf Cascorbi and Adrian Llerena.

The congress will provide the opportunity for researchers and clinicians to come together and share their research and experiences in basic, clinical and translational fields.

Young researchers and clinicians are especially invited to join us in Copenhagen to share and discuss their input with the attendees.

The congress will have poster presentations from abstracts that were sent in. Selected abstracts have been added to the program for oral presentations.

So please join us to expand our knowledge and network and make new friends.

See you in Copenhagen!

Prof. Dr. Lona Louring Christrup
DSPM President

Prof. Dr. Ann Daly
ESPT President

ESPT Board

Ann Daly
Ron van Schaik
Vangelis Manolopoulos
Vita Dolzan
Sanja Stankovic
Tiffany Morris
Csilla Sipeky
Mikko Niemi
Adrian Llerena

DSPM Board

Lona Louring Christrup
Kim Dahlhoff
Morten Baltzer Houlind
Niels Westergaard
Trine Rune Høgh
Jon T Andersen
Michael Asgar Andersen

Organizing Committee

Ann Daly
Mikko Niemi
Ron van Schaik
Lona Louring Christrup
Niels Westergaard
Kim Dalhoff

Speakers

Akkers Robert - Results Laboratorium, Dordrecht, The Netherlands
Alix-Panabieres Catherine - Laboratory of Rare Human Circulating Cells, CHU de Montpellier, France
Bjerregaard Stage Tore - Head of Research, Associate Professor, University of Southern Denmark, Odense
Brøsen Kim - Clinical Pharmacology, Pharmacy and Environmental Medicine, Odense, Denmark
Brown Matt - Chief Scientific Officer, Genomics England, London, UK
Cascorbi Ingolf – Director Institute of Experimental and Clinical Pharmacology University Hospital Schleswig-Holstein, Kiel, Germany
Cecchin Erika - Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
Coenen Marieke - Associatie Professor Pharmacogenetics at ErasmusMC, Rotterdam, The Netherlands
Daly Ann - Chair, European Society of Pharmacogenomics and Personalised Therapy, Translational and Clinical Research Institute, Newcastle upon Tyne, UK
Dorfman Ruslan - Chief Scientific Officer, Pillcheck, Ontario, Canada
Elmedal Laursen Britt - Associate Professor, Department of Biomedicine, Aarhus University, Denmark
Ingelman-Sundberg Magnus - Professor Department of Physiology and Pharmacology, Section of pharmacogenetics, Karolinska Institutet, Stockholm, Sweden
Johansen Peter - Senior Adviser, Nationalt Genom Center, Copenhagen, Denmark
Klomp Sylvia - Dept. of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, The Netherlands
Lindbjerg Andersen Claus - Professor, Group Leader and Director of the National Danish ctDNA Research Center, Aarhus, Denmark
Louring Christrup Lona - Professor Emeritus, Translational Pharmacology, University of Copenhagen, Denmark
Llerena Adrian - Professor Clinical Pharmacology, INUBE Biosanitary University Research Institute, Badajoz, Spain
Manolopoulos Vangelis - Professor of Pharmacology, Pharmacogenomics, and Precision Medicine, Alexandroupolis Greece
Molden Espen - Professor of Pharmacology, School of Pharmacy, University of Oslo, Norway
Mueller Daniel - Psychiatrist, Senior Scientist at CAMH and Associate Professor at University of Toronto, Canada
Newman William - Professor of Translational Genomic Medicine in The Manchester Centre for Genomic Medicine at the University of Manchester, UK
Niemi Mikko - Professor, Department of Clinical Pharmacology, University of Helsinki, Finland
Pantel Klaus - Director of Institute of Tumor Biology and Full Professor at University Hospital Hamburg-Eppendorf, Germany
Sir Pirmohamed Munir – Professor at Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, UK
Pratt Vicky - Clinical Associate Professor, Medical and Molecular Genetics and Director, Scientific Affairs for Pharmacogenetics, Indiana, USA
Samer Caroline - Head of the Clinical Pharmacology and Toxicology Division, Geneva University Hospitals, Swiss
Swen Jesse - Professor of Clinical Pharmacy and Section Chair of the Laboratory, Leiden University Medical Center, The Netherlands
Van den Broek Wout - PhD Candidate Cardiology, St. Antonius Hospital Nieuwegein, The Netherlands
Woodahl Erica - Professor in the Department of Biomedical and Pharmaceutical Sciences, Skaggs School of Pharmacy, University of Montana, USA

25-26 OCTOBER

25 WEDNESDAY October

12:30 - 14:30 ESPT Executive Board meeting – Closed Meeting
15:00 - 15:45 Meeting with ESPT National Representatives – Closed Meeting
16:00 - 17:00 ESPT General Assembly

13:00 - 18:00 Pre - Registration
18:00 - 19:30 OPENING RECEPTION at the congress venue DGI-Byen

26 THURSDAY October

07.30 Registrations open
08:45 Opening and Welcome - Lona Louring Christrup
Welcome on behalf of ESPT - Ann Daly

SESSION: PGx CLINICAL IMPLEMENTATION
Chairs: Lona Louring Christrup & Ann Daly

09:00 A historic overview of pharmacogenetics: Kim Brosen's perspective – Kim Brøsen (Keynote Lecture)
09:30 Implementing pharmacogenomic panel testing in Europe: experiences from the U-PGx PREPARE study – Jesse Swen
09:55 Pharmacogenomics beyond single common genetic variants: the way forward – Magnus Ingelman-Sundberg

10:20 - 10:50 COFFEE BREAK

SESSION: PSYCHIATRY
Chairs: Sanja Stankovic & Michael Asger Andersen

10:50 PGx-guided precision dosing of antidepressants – all settled? Espen Molden
11:15 Applying PGx in Psychiatry: Taking things personally – Daniel Mueller
11.40 Real World Pharmacogenetic experience from a Canadian perspective – Ruslan Dorfman
12:05 Global Diversity Array with enhanced PGx as a method for panel PGx testing: results of a validation study with samples from the PREPARE study – Sylvia Klomp
12:30 Cost-effectiveness of pharmacogenomic-guided treatment: results from a microsimulation model for major depression (selected abstract) - Shahzad Ghanbarian & Louisa Edwards

12:45 - 13:45 LUNCH / POSTER VIEWING /BOOTHS VISIT

SESSION: ONCOLOGY
Chairs: Mikko Niemi & Niels Westergaard

13:45 DPYD pharmacogenetics: the long and winding road to precision dosing of fluoropyrimidines – Erika Cecchin
14:10 Addressing phenoconversion with the Geneva phenotyping cocktail: clinical experience – Caroline Samer
14:35 Drug transporters and novel biomarkers in chemotherapy-induced peripheral neuropathy – Tore Bjerregaard Stage
15:00 Clinical opportunities for germline pharmacogenetics and management of drug-drug interactions in patients with advanced solid cancers – Vicky Pratt
15.25 Germline variants are associated with clinical outcomes and pharmacokinetics in patients with ALK+ NSCLC treated with alectinib (selected abstract) - Niels Heersche

15:40 - 16:10 TEA BREAK

SESSION: ctDNA
Chairs: Ron van Schaik & Vita Dolzan

16:10 Liquid Biopsy: From Discovery to Clinical Implementation
Klaus Pantel (Keynote Lecture)
16:40 Circulating Tumor DNA for Minimal Residual Disease Detection and Risk-Stratified Recurrence Surveillance – Claus Lindbjerg Andersen
17:05 The power of circulating tumor cells in immuno-oncology
Catherine Alix Panabieres

17:30 CLOSURE

20:00 CONGRESS DINNER

27 FRIDAY October

SESSION: PGx CHALLENGES
Chairs: Ron van Schaik & Kim Dahlhoff

08:45 Pharmacogenomics of Adverse Drug Reactions
Sir Munir Pirmohamed (Keynote Lecture)
09:15 The future of PGx testing; lessons from the 100,000 Genomes project
Matt Brown (Keynote Lecture)
09:40 Pharmacogenomics with Rural and Indigenous Communities
Erica Woodahl

26-27 OCTOBER

10:05 - 10:35 COFFEE BREAK

SESSION: CARDIOLOGY
Chairs: Adrian Llerena & Vangelis Manolopoulos

10:35 Impact of Implementing CYP2C19 Genotype Guided Antiplatelet Treatment in Clinical practice – Wout van den Broek
11:00 Statin pharmacogenetics – clinical relevance and implementation Mikko Niemi
11:25 Pharmaco(epi)genomics of oral anticoagulation therapy with DOACs Vangelis Manolopoulos
11:50 Pharmacogenetics in clinical practice, experience and expectations of pharmacogenetic tests – Marieke Coenen
12:15 Exploring the Genetic Basis of Dyspnea in Individuals Treated with Ticagrelor (selected abstract) – Marc-Olivier Pilon

12:30 - 13:30 LUNCH / POSTER VIEWING /BOOTHS VISIT

SESSION: PERSONALISING DRUG TREATMENT
Chairs: Vita Dolzan & Morton Balzer

13:30 Cocktail approach of probe drugs applying GWAS: further variants of relevance? – Ingolf Cascorbi
13:55 Clinical scenarios where point of care pharmacogenetic testing improves outcome – William (Bill) Newman
14:20 OPRA (Oncology Precision Project Aarhus); Pharmacogenomically guided treatment for cancer patients – Britt Elmedal Laursen
14:45 Identification of DPYD copy number variation in Finnish population using high-throughput next generation sequencing (selected abstract) – Sofia Khan

15:00 - 15:30 COFFEE BREAK

SESSION: FOCUS ON THE FUTURE
Chairs: Csilla Sipeky & Jon Thor Traerup Andersen

15:30 Progress at the Danish National Genome Center – Peter Johansen
15:55 Using NGS for PGx – Robert Akkers
16:20 Clinical Pharmacogenetics Implementation in Spanish Health Service (MedeA, IMPaCTm BiofRAM) – Adrian Llerena

16:45 POSTER PRIZE

17:00 CLOSURE

28 SATURDAY October

Discussion Forum: How to move forward with implementing PGx?

9:30 - 10:00 WELCOME COFFEE

10:00 - 10:45 PANEL SESSION 1: IMPLEMENTATION

SHORT INTRO: Reflection on implementation of PGx in UK
Sir Munir Pirmohamed, MD/PhD
Erika Cecchin, Italy (Oncology)
Britt Elmedah Laursen – Denmark (Oncology)
Adrian Llerena, Spain (PGx-implementation)
Daniel Mueller, Canada (Psychiatry)
William (Bill) Newman, England (Clinical Genetics)
Mikko Niemi, Finland (PGx services)
Jesse Swen, The Netherlands (PGx-services)

10:45 - 11:15 PANEL SESSION 2: INDUSTRY VIEW

SHORT INTRO: Pgx in the near future: a laboratory perspective
Daniel Langhoff, Director Eurofins Genomics, Denmark
Ruslan Dorfman, Pillcheck Canada
Tiffany Morris, Illumina
Vicky Pratt, AGENA Bioscience
Dominique Dewolf, Thermo Fisher Scientific

11:15 - 11:45 PANEL SESSION 3: PGx RESEARCH

SHORT INTRO: Which (additional) research is needed?
Magnus Ingelman-Sundberg, Karolinska Instituten, Sweden
Matt Brown, Biobank, Genomics England
Kim Brøsen, Clinical Pharmacology - Denmark
Ingolf Cascorbi, Clinical Pharmacology - Germany

11:45 CLOSURE + Announcement 2025 ESPT venue - Ann Daly

General Information

Congress Venue

DGI Byen
CPH Conference
Tietgensgade 65
1704 Copenhagen
https://www.dgibyen.dk/en/practical-information/practical-information/



Posters

DGI Byen
Posters are displayed in the Plenary Room,
Auditorium Sankt Hans Torv & Nørrebros Runddel.

Posters are arranged by topic and displayed on two different days:
- Thursday, 26 October 08:00 - 17:30
- Friday, 27 October 08:00 - 17:00

Posters are numbered and must be on display ONLY on the day assigned to the author.

The Organising Secretariat does not take any responsibility for posters left on display afterwards. Posters left on display after the agreed time, will NOT be stored.

To encourage discussion, poster presenters are asked to be at the assigned poster panel during the breaks.

The Poster Evaluation Committee and the congress Attendees will vote the best ones and the two winners will be announced on Friday 27 October at the end of the scientific sessions.

The winning posters will be uploaded on https://www.esptcongress.org/

WI-FI Connection

Wi-Fi connection will be available in the whole congress venue;
please choose
CHP Conference
on the network.
Password: dgibyenwifi

Official Language

All lectures will be in English.

Badges

All registered participants, speakers and exhibitors will be given a badge, which they must mandatorily wear within the congress areas all days long.

Certificate of Attendance

Certificates of attendance will be sent by e-mail to all registered attendees after the congress.

Lunch and coffee break

Lunches and coffee breaks will be served only in the Auditorium Foyer.

Congress Dinner

(not included in the registration fee)
The Congress Dinner will be held at the congress venue on Thursday, 26 October at 20.00 at Østerbro Rooftop Restaurant

Tickets can be purchased on site, if still available: €75 per person

Exhibition Opening Hours

THURSDAY 26 October	08:00 – 17:30
FRIDAY 27 October	08:00 – 17:00
SATURDAY 28 October	09:30 – 12.00

The Exhibition Area is located in the Auditorium Foyer

Posters

26 THURSDAY October

Clinical implementation

T01
STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline
M. Chaplin, J. Kirkham, K. Dwan, D. Sloan, G. Davies, A. Jorgense

T02
Pharmacogenomic Variants of Medically Important Adverse Effects Related to High-Risk Medicines in General Practice Can Not Be Replicated in UK Biobank
K. Mokbel, M. Weedon, L. Jackson

T03
Randomized clinical trial to determine the usefulness of training prescribers in pharmacogenetics and of SLCO1B1, ABCG2 and CYP2C9 genotyping in the prescription of statins in primary and specialized care: The AP-PriME project
P. Zubiaur, F. Abad-Santos, W.G. Ap-Prime

T04
Utilization of newly initiated pharmacogenetically relevant drugs in hospital-treated patients – a descriptive study using Finnish drug dispensation data
N. Kulla, K. Litonius, K. Cajanus, V. Kytö, M. Niemi, A. Tornio

T05
Personalized Antiplatelet Therapy based on Point-of-Care CYP2C19 Pharmacogenetics plus Multidimensional Treatment Decisions in a Cohort of 167 Patients
V. Voicu, N. Diehm, I. Moarof, S. Parejo, A. Burden, M. Béchir, S. Russmann

T06
Implementation of CYP2D6 Pharmacogenetics and Therapeutic Drug Monitoring for Personalized Tamoxifen Breast Cancer Therapy
J. Bühler, N. Hauser, C. Elfgen, A. Burden, V. Voicu, M. Béchir, S. Russmann

T07
Pharmacogenetic pilot study focused on the toxicity in pediatric oncologic patients`
M.J. Herrero, G.G. Olivera, L. Sendra, E.G. Zucchet, A. Juan-Ribelles, M.d.M. Andrés, J. Balaguer, A. Cañete, S.F. Aliño

T08
Development of an interoperable pharmacogenetic service for the NHS: The PROGRESS programme
J. Mcdermott, J. Keen, V. Sharma, D. Stoddard, R. James, A. Taylor, G. Dalal, P. Wilson, K. Payne, M. Pirmohamed, W. Newman

T09
Pharmacogenetic Studies and Testing Options in Bangladesh: Current Status, Implementation Challenges, and Future Directions
M.A. Aziz, M.S. Mostaid, A.A. Maruf

T10
Implementation of pharmacogenetics in Dutch primary care: evaluation current clinical practice and potential hurdles
D. Van der Drift, M. Simoons, B. C.P. Koch, G. Brufau, P. Bindels, M. Matic, R. H.N. van Schaik

T11
Organization and fifteen years experience of a Pharmacogenetics unit within a Hospital Pharmacy Service
T. Irene, G. Xandra, S. Sara, Z. Paula, H. Ana, S. María, L. Luis Andrés

T12
Determining the cost-utility of pre-emptive genetic testing: an umbrella review
T. Ochi, M. Den Uil, G. Piazza, G. Frederix, E. Hak, V. Deneer, T. Feenstra

Oncology

T13
Design of a Custom Genotyping Card to Identify Genetic Variants Associated with Adverse Reactions to Bortezomib in Multiple Myeloma: Towards Personalized Therapy
M. Saiz-Rodríguez, A. Sanz-Solas, J. Labrador, R. Alcaraz, R. Vinuesa, M.V. Cuevas, B. Cuevas

T14
Genomic profiling indicates distinct differences between gynaecological cancer types, aiding personal treatment selection
J. Vlaeminck, F. Vaeyens, P. Giron, K. Maes, F. Hes

T15
Influence of ABCB1 Polymorphisms on the Incidence of Adverse Reactions to Bortezomib in Multiple Myeloma Patients
A. Sanz Solas, J. Labrador, R. Alcaraz, R. Vinuesa, M.V. Cuevas, B. Cuevas, M. Saiz Rodriguez

T16
Preclinical and clinical evaluation of cumulative effects of TPMT and NUDT15 on thiopurines-induced toxicity
M. Maillard, W. Yang, C.E. Haidar, D. Chepyala, S.H. Lee, K. Hoshitsuki, J. Hunt, J.Q. Nguyen, M.V. Relling, K.R. Crews, M. Leggas, A.E.J. Yeoh, F.G. Antillon Klussmann, S.E. Karol, D. Bhojwani, J.J. Yang

T17
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer
E. Peruzzi, L. Gerratana, M. Montico, B. Posocco, S. Corsetti, M. Bartoletti, S. Gagno, M. Orleni, E. De Mattia, G. Toffoli, F. Puglisi, E. Cecchin, R. Roncato

T18
Germline variants are associated with clinical outcomes and pharmacokinetics in patients with ALK+ NSCLC treated with alectinib
N. Heersche, D.A.C. Lanser, T.A.M. Trooster, M.I. Mohmaed Ali, E. De Jonge, E. Oomen-De Hoop, A.C. Dingemans, A.D.R. Huitema, R.H.N. Van Schaik, G.D.M. Veerman, R.H.J. Mathijssen

T19
Single-centre experience of CYP2C19 genotype- and TDM-guided voriconazole application in haemato-oncology adult patients
S. Kirschke, T. Klein, M. Schwarz, S. Forkl, K. Spiekermann, M. Von Bergwelt, D. Strobach, H. Mannell

T20
Predicting phenotypes by combining genetic, epigenetic and clinicopathological profiles of colorectal cancer patients
P. Esperón, M. Vital, F. Carusso, C. Vergara, F. Neffa, A. Della Valle

T21
Role of Single Nucleotide Polymorphisms in DNA Repair Genes on the toxicity of Capecitabine-Based Therapy in Colorectal Cancer Patients
Y. Cura, A. Sánchez-Martín, C. Pérez-Ramírez, E. González-Flores, A. Jiménez-Moráles

T22
Irinotecan-Induced Toxicity: A pharmacogenetic Study beyond UGT1A1
M. De With, L. Van Doorn, E. Kloet, A. Van Veggel, M. Matic, M.J. De Neijs, E. Oomen-De Hoop, E. Van Meerten, R.H. Van Schaik, R.H. Mathijssen, S. Bins

T23
PERSONALIZED ONCOLOGY PATIENT THERAPIES
V. Moreno Moral, S. Barrero Luque, D. Rodriguez Cano, A. Martinez Peinado, F. Rodriguez Cantalejo

T24
HEREDITARY BREAST CANCER: PERSONALIZED THERAPIES
V. Moreno Moral, D. Rodriguez Cano, S. Barrero Luque, A. Martinez Peinado, F. Rodriguez Cantalejo

T25
Personalized therapy approach for tamoxifen in breast cancer
Z.G. Ozunal

Psychiatry

T26
Association between vitamin B12 metabolism related indicators and polymorphism of TCN-2 gene in postpartum women with postpartum depression
P. Dhiman, S. Rajendiran, R.R. Pillai, B. Bharadwaj, V. Ranjan

T27
Effectiveness of genotype-guided tricyclic antidepressant dosing in patients with major depressive disorder: a randomized clinical trial
C. Vos, S. Ter Hark, A. Schellekens, J. Spijker, v.d.M. Annemarie, A. Grotenhuis, R. Mihaescu, R. Donders, W. Kievit, R. Aarnoutse, M. Coenen, J. Janzing

T28
Impact of CYP2B6, CYP2C19 and the CYP2C:TG haplotype on formation of sertraline metabolites in vivo
L.S. Bråten, E. Molden, M.K. Kringen

T29
Identification of a NDUFA6-DT haplotype reducing CYP2D6 metabolism of risperidone
M. Zidan, E. Størset, E. Molden, M.K. Kringen

T30
Impact of CYP2D6 genotype on risperidone treatment - A retrospective analysis based on clinical data from the Daybreak study
T. Frederiksen, B. Nørgaard Madsen, E. Schmidt, J. Areberg

T31
Cost-effectiveness of pharmacogenomic-guided treatment: results from a microsimulation model for major depression
S. Ghanbarian, G.W. Wong, M. Bunka, L. Edwards, S. Cressman, T. Conte, M. Price, C. Schuetz, L. Riches, G. Landry, D. Erickson, K. Mcgrail, S. Peterson, R. Vijh, A.M. Hoens, J. Austin, S. Bryan

T32
Challenges in Interpreting TDM and PGx Results: A Case Report on Adverse Drug Reactions under Clozapine Treatment
F.M. Wiss, H.E. Meyer Zu Schwabedissen, S.S. Allemann, C.K. Stäuble, M.L. Lampert

T33
I-PILOT: Real World Implementation of Pharmacogenomics in NHS clinical pathways for Mental Health
A. Tennant, J. Woodley, A. Skowronska, G. Rees, J. O'Brien, S. Abbs, B. Pinder, J. Bell

T34
Sex-dependent association of the MAOA rs979605 genetic polymorphism on clinical improvement following antidepressant treatment in depressed patients
K. Chappell, R. Colle, J. Bouligand, S. Trabado, B. Fève, L. Becquemont, E. Corruble, C. Verstuyft

T35
Frequency of CYP2D6, CYP2C19, CYP1A2, CYP3A5 and CYP2C9 major alleles in Greek psychiatric patients: Implications for antidepressant and antipsychotic dose adjustments
G. Ragia, M. Pallikarou, Y. Manolopoulou, T. Vorvolakos, M. Samakouri, V. Manolopoulos

T36
Evaluation of Pharmacogenetic Testing for Methylphenidate Treatment Prediction in Childhood Attention Deficit Hyperactivity Disorder in Turkish Population: Focus on Carboxylesterase1, Latrophilin-3 and Catechol-O-methyltransferase Gene Polymorphisms
I. Suzer Gamli, R.S. Karaaslan, A.V. Veggel, A. Hodzic Kurec, Z. Marzoukah, G. Bulut, H. Tunc, I. Adak, C. Hizel Perry, C. Parlayan, O. Ekinci, R.R.V. Schaik, D. Akin

T37
GWAS comparison of clozapine and risperidone treated patients with psychotic disorders
H. Çağın Lenk, K.S. O'Connell, R. Løvsletten Smith, I.A. Akkouh, S. Djurovic, O.A. Andreassen, E. Molden

07 FRIDAY October

Cardiology

F01
Common P-glycoprotein (ABCB1) polymorphisms do not seem associated with the risk of bleeding in rivaroxaban-treated patients: preliminary data from a nested case-control study
A.M. Slišković, J. Palić, T. Božina, L. Ganoci, V. Pašara, M. Vrkić Kirhmajer, V. Trkulja, J. Bulum, L. Šimičević

F02
Genome-wide association study of atorvastatin pharmacokinetics: associations in SLCO1B1, UGT1A3, and LPP
A.J.H. Mykkänen, E.K. Tarkiainen, S. Taskinen, M. Neuvonen, M. Paile-Hyvärinen, T. Lilius, T. Tapaninen, J.T. Backman, A. Tornio, M. Niemi

F03
The potential role of CYP2J2 pharmacogene in cardiovascular disease
L. Šimičević, M. Jurič, A.M. Slišković, J. Palić, L. Ganoci, T. Božina, D. Rogić

F04
Identification of clinical and pharmacogenetic predictors of response to direct oral anticoagulants in the treatment of nonvalvular atrial fibrillation.
G. Villapalos-García, P. Zubiaur, J. Novalbos, A. Rodriguez-López, G. Mejía-Abril, A. Casajús-Rey, D. Campodónico, G. Doac-19, F. Abad-Santos

F05
Effects of statins on rat myotube cell viability and metabolomics
P. Hirvensalo, L. Salonen, A. Filppula, S. Lehtonen, M. Niemi

F06
PLK2 METHYLATION AS A PHARMACOEPIGENOMIC BIOMARKER IN DIRECT ORAL ANTICOAGULANT THERAPY: PREDICTING ADVERSE BLEEDING EVENTS IN ATRIAL FIBRILLATION PATIENTS
N. Atzemian, A. Maslarinou, G. Ragia, V. Tsaliki, T. Thomopoulos, G. Chalikias, G. Kolios, A. Trikas, D. Tziakas, V.G. Manolopoulos

F07
SLCO1B1 and statin pharmacogenomics – frequencies and impact of increased function variants and haplotypes – real life data
L. Ganoci, J. Palić, L. Šimičević, E. Karačić, I. Mucalo, N. Božina, I. Pećin, M. Lovrić Benčić, T. Božina

F08
Exploring the Genetic Basis of Dyspnea in Individuals Treated with Ticagrelor
M. Pilon, K. Saliba, A. Barhdadi, S. Provost, G. Asselin, L. Lemieux Perreault, D. S Paul, N. Eriksson, L. Wallentin, J. Tardif, S. De Denus, M. Dubé

Decision support

F09
Barriers to the implementation of pharmacogenomic discovery
T. Stenta, M. Assis, B. Felmingham, C. Moore, D. Khatri, D. Elliot, R. Conyers

F10
Influence of genetics on the response to omalizumab in patients with severe uncontrolled asthma with an allergic phenotype
S. Rojo-Tolosa, J.A. Sánchez-Martínez, C. Morales-García, A. Jiménez-Morales

F11
Artificial Intelligence / Machine Learning (AI/ML) to Identify potential therapy choices that could enhance efficacy and minimize adverse reactions in lung cancer
R. Gopalan

Drug transporters

F12
Inhibition of efflux transporters by poly ADP-ribose polymerase (PARP) inhibitors
F. Deng, J. Sistonen, M. Neuvonen, M. Niemi

F13
Establishment of an ABC transporter knockout platform for substrate characterization using CRISPR/Cas9-genome editing
M. Kaehler, A. Kasten, S. Oswald, I. Vater, M. Spielmann, I. Cascorbi

F14
Impact of genetic variants in relevant pharmacogenes on the pharmacokinetics, pharmacodynamics and safety of valsartan, olmesartan and hydrochlorothiazide.
P. Soria-Chacartegui, P. Zubiaur, D. Ochoa, G. Villapalos-García, E. González-Iglesias, A. Rodríguez-López, G. Mejía-Abril, M. Navares-Gómez, S. Martín-Vílchez, C. Méndez-Benegassi, S. Luquero-Bueno, F. Abad-Santos

F15
Comparative Analysis of 3rd Generation Stony Brook Taxanes on Gene Expression of Drug Transporters, Metabolism Genes, and NOTCH Signaling Pathway in a Resistant Ovarian Carcinoma Model
K. Seborova, A. Spalenkova, K. Koucka, P. Holy, M. Ehrlichova, L. Chen, H. Bendale, I. Ojima, P. Soucek, R. Vaclavikova

F16
Effect of single nucleotide polymorphisms of organic cation transporter 3 on pharmacokinetics of metformin
H. Chung, D. Shin

F17
Ticagrelor markedly increases plasma concentrations of the breast cancer resistance protein substrate rosuvastatin
M. Lehtisalo, E.K. Tarkiainen, M. Neuvonen, M. Holmberg, J.I. Kiiski, O. Lapatto-Reiniluoto, A.M. Filppula, M. Kurkela, J.T. Backman, M. Niemi

F18
Inhibition of most common placental transporters by 200 drugs commonly used during pregnancy
S. Tuomi, F. Deng, M. Ellfolk, H. Malm, A. Tornio, M. Niemi

F19
Untargeted metabolomics and machine learning for the identification of plasma metabolites associated with organic anion transporting polypeptide 1B1 function
K. Hämäläinen, M. Neuvonen, P. Hirvensalo, M. Lehtonen, S. Auriola, A. Tornio, J.T. Backman, M. Niemi

F20
Pharmacogenomics of atorvastatin – the role of SLCO1B1 increased function variants and haplotypes
L. Ganoci, J. Palić, L. Šimičević, L.A. Bićanić, I. Mucalo, I. Pećin, D. Leskovar, T. Božina

F21
Pharmacogenomics of atorvastatin and rosuvastatin – the ABCG2 and risk for development of myotoxicity and hepatotoxicity
J. Palić, L. Ganoci, L. Bićanić, L. Šimičević, I. Mucalo, I. Pećin, D. Leskovar, T. Božina

Genotyping

F22
Simultaneous Profiling of SNP Genotyping and Copy Number Variation Using 96 Assays in a Nanofluidic Platform for Pharmacogenomics Studies
J. Moore, H. Ren, K. Amit, T. Goralski, A. Julie, H. Win, P. Charles, D. King, N. Ramalingam

F23
Establishment of a robust, largely automated and cheap in-house DPYD genotyping protocol
P. Bøttger, J. Skov Madsen

F24
Characterization of germline and somatic genetic profiles of epithelial ovarian carcinoma patients sensitive and resistant to platinum derivatives and association with therapy outcome
R. Vaclavikova, V. Hlavac, P. Holy, K. Seborova, M. Aoa, M. Hruda, L. Rob, M. Mrhalova, A. Bartakova, J. Bouda, V. Smoligova, J. Spacek, I. Sedlakova, P. Soucek

F25
Empowering Individuals through Whole Genome Sequencing: A Pharmacogenetics Approach for Personalized Medicine
M.A. Andersen, P. Damkier

F26
Identification of DPYD copy number variation in Finnish population using high-throughput next generation sequencing
S. Khan, J. Kiiski, M. Niemi

F27
Genotype and Phenotype Agreement of CYP2D6, CYP2C19, and CYP2C9: Comparison of Public Pharmacogenetic Tests in Denmark
M. Baltzer Houlind, E. Iversen, L. Hansen, H. Berg Rasmussen, J. Borggaard Larsen, L. Christrup, N. Westergaard, .. Optinam-Comp Research Team

Internal Medicine

F28
TLR4 Receptor D299G/T399I Haplotype Polymorphism Is Associated with Insulin Resistance in Obese Female Subjects
E. Sharif, M. Alwakeel, N. Rizk

F29
Genotype informed Bayesian dosing of tacrolimus in solid organ transplant - Pharmacogenomic Implementation in Children
D. Khatri, B. Felmingham, D. Metz, C. Moore, L. Smaro, T. Stenta, D. Elliott, R. Conyers

F30
Gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel disease
S. Salvador-Martín, G. Rubbini, P. Velosillo, P. Zapata-Cobo, M. Sanjurjo-Sáez, X. García-González, L.A. López-Fernández

F31
Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
P. Zapata-Cobo, S. Salvador-Martín, M. Sanjurjo-Sáez, X. García-González, L.A. López-Fernández

F32
Pharmacogene variants associated with kidney transplant in a fifteen-year clinical follow-up
L. Sendra, G. Olivera Pasquini, M. Bresó Pla, D. Hervás Marín, J. Hernández, I. Beneyto, F.D.V. Genvigir, S.F. Aliño, M.J. Herrero

F33
MIADR in adolescent CYP2D6 poor metabolizers
C. Nofziger, F. Fink, M. Bognar, P. Hengl, M. Paulmichl

F34
Use of drugs with Pharmacogenomics (PGx)-Based Dosing Guidelines in a Danish Cohort of Persons with Chronic Kidney Disease, Both on Dialysis and Not on Dialysis: Perspectives for Prescribing Optimization
M. Baltzer Houlind, N. Westergaard, L. Louring Christrup, H. Gybel Juul-Larsen, C. Strandhave, E.O. Anne

Pain management

F35
Pharmacogenotyping disproves genetic cause of drug-related problems in family history – a case report
A. Bollinger, K.E. Hersberger, H.E. Meyer Zu Schwabedissen, S.S. Allemann, C.K. Stäuble

F36
Tramadol, O-Desmethyltramadol and N-Desmethyltramadol after major abdominal surgeries with respect to CYP2D6 and COMT genetic variants
N. Nešković, S. Marczi, D. Mandić, S. Škiljić, G. Kristek, H. Vinković, Ž. Debeljak, S. Kvolik

F37
TRADOL-PriME: a randomized clinical trial to evaluate the utility of CYP2D6 genotyping to improve the efficacy and safety of tramadol in the treatment of acute postoperative pain
F. Abad-Santos, P. Soria-Chacartegui, E. González-Iglesias, G. Mejía-Abril, M.F. Muñoz-Guerra, P. Zubiaur, A. Borobia, M.Á. Gálvez-Múgica, I. García-García, L. Llanos-Jiménez, S. Almenara De Riquer, P. Zapater, M. Saiz-Rodríguez, A. Portolés-Pérez, B. Ruiz-Antorán, J. Novalbos

F38
A comprehensive pilot care program for people suffering chronic sensitive or emotional pain and opioid use disorders. Can pharmacogenetics help
X. Garcia-Gonzalez, J. Guerra, L. Gonzalez, A. Gimenez-Manzorro, M.L. Martin-Barbero, M. Peña-Granger, M.L. Cuesta-Santamaria, N. Szerman, L.A. Lopez Fernandez

F39
Is there any association between CYP2D6 genotype and labour pre-epidural pain?
I. Erenas Ondategui, N. García Cuadrado, C. Chicharro Miguel, V. Velasco González, M. Sainz Gil, A.M. Fernández Araque, F. Bandrés Moya, M. Grazina, Z. Verde Rello

Personalised Therapy

F40
Genetic Association of Angiotensin-Converting Enzyme 1 (ACE1) Polymorphism with COVID-19 Susceptibility and Severity Among Circassians and Chechens in the Jordanian Population: a Retrospective Study
N. Hakooz, R. Saadeh, L. Al-Eitan, R. Dajani, S. Abudahab

F41
A Longitudinal Study on the Impact of SARS-CoV-2 Infection on the Profile of Microbiota and Host Immune Responses: potential mechanisms and therapeutic interventions
R.R. Mani

F42
Differences in gut microbiota between genders in patients with coronary artery disease.
D. Rodriguez Cano, H. García-Fernández, J. López-Moreno, J. Jiménez-Torres, A. Vegas-Rojas, J.D. Torres-Peña, J. Delgado-Lista, J. López-Miranda, A. Camargo

F43
Genetic Variants Associated with Subclinical Carotid Atherosclerosis in a Korean Population
K. Park, J. Park, J. Woori

F44
Effect of Vitamin D Deficiency on Poor Glycemic Control and Cardiovascular Risk in Diabetes
A. Chaudhary

F45
Longitudinal profile of antibody response to SARS-CoV-2 in patients with COVID-19 in a setting from Sub–Saharan Africa: A prospective longitudinal study
T. Gebrecherkos

Platinum Sponsors

Gold Sponsors

Silver Sponsors

Organising Secretariat
MZ Events
T. +39 0266802323
info@esptcongress.org
registrations@esptcongress.org

European Society of Pharmacogenomics and Personalised Therapy
A Scientific Society for Individualised Medicine

European Society of Pharmacogenomics and Personalised Therapy
www.esptsociety.eu

www.esptcongress.org